Thermo Fisher Scientific

What Thermo Fisher Scientific does

Thermo Fisher Scientific (NYSE: TMO) is a publicly traded life sciences conglomerate founded in 1956 and headquartered in Waltham, Massachusetts, operating across four primary domains: analytical instruments, clinical diagnostics, laboratory products, and biopharma services. Its instrument portfolio centers on mass spectrometry (Orbitrap Tribrid Apex, Excedion, and Exploris GC S platforms), electron microscopy (Selectris and Glacios 3 Cryo-TEM systems), genomics and molecular diagnostics (Applied Biosystems TaqMan, QuantStudio 5 Dx, Ion Torrent sequencers, RapidHIT ID for forensic DNA), proteomics (Olink PEA technology enabling analysis of 5,400+ proteins), chromatography, and HLA/transplant diagnostics (One Lambda). The company sells consumables (antibodies, cell culture media, chemicals, oligos) through the Fisher Scientific marketplace offering over 2.5 million products globally, and provides end-to-end biopharma services via Patheon (CDMO with 60+ global sites covering API, biologics, viral vectors, sterile fill-finish, commercial manufacturing) and PPD (CRO services plus CorEvitas real-world evidence registries), with Clario (acquired March 2026 for $8.875B) adding digital endpoint data solutions for clinical trials.

The business model combines multiple revenue streams: instrument hardware sales, recurring consumables, subscription-based service plans through Unity Lab Services (2,000+ factory-certified engineers), project-based CDMO/CRO engagements under long-term contracts, and clinical diagnostics distributed through hospitals and reference laboratories. Pricing spans list, contract/institution, and online-exclusive tiers for products, with annual subscriptions for service plans and customized enterprise agreements. Customers span pharmaceutical and biotechnology companies (primary), clinical laboratories and healthcare providers (primary), CDMOs (primary), academic and government research institutions, industrial and applied sciences customers, and molecular diagnostics companies, served through direct enterprise field sales, the thermofisher.com e-commerce platform, regional distribution hubs, and dedicated PPD/Patheon account teams. The company generated $44.56 billion in FY2025 revenue with Q1 2026 revenue of $11.01 billion (6% YoY growth), targeting $54.1 billion by 2029 at a 7% organic revenue CAGR within a $255 billion addressable market.

Recent strategic actions include the Clario acquisition ($8.875B, March 2026), the Solventum Purification & Filtration business acquisition (~$4.1B, September 2025), the divestiture of the microbiology business to Astorg (~$1.075B, November 2024), $11.3 billion in debt issuance across 2022-2026, and a coordinated AI partnership buildout with NVIDIA, OpenAI, TetraScience, and BenchSci announced at BIO International 2026. Leadership underwent a January 2026 transition in which COO Michel Lagarde and EVP Frederick Lowery departed and Gianluca Pettiti was promoted to President and COO, while continuing product launches in Orbitrap, Olink, and Cryo-TEM platforms have reinforced the technology portfolio.

Name

Thermo Fisher Scientific

Legal name

Thermo Fisher Scientific Inc.

Website

https://thermofisher.com

Company type

Public

Founded year

1956

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Thermo Fisher Scientific (NYSE: TMO), founded 1956 and headquartered in Waltham, MA, is a diversified life sciences conglomerate providing analytical instruments, clinical diagnostics, laboratory consumables, and biopharma CDMO/CRO services to pharmaceutical, biotechnology, clinical laboratory, academic, and industrial customers across global markets.

Ownership category

akta.pro rank

Product category

Life Sciences Tools and Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Pharmaceutical Preparation Manufacturing (325412)

SIC

Laboratory Analytical Instruments (3826), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Services-Medical Laboratories (8071)

akta.pro primary industry

Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)

akta.pro secondary industries

Analytical Instruments & Chromatography Systems (HLAGAIAA), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Laboratory Consumables & Plasticware (Tips, Tubes, Plates, Filters) (HLAGAIAH), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Analytical laboratory instruments
• Life sciences reagents
• Clinical diagnostics products
• Pharmaceutical CDMO services
• Mass spectrometry equipment

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Products and Biopharma Services Segment: The Laboratory Products and Biopharma Services segment accounts for more than half of quarterly revenue (Q1 2026: $6.036 billion). This segment includes instruments, equipment, consumables, chemicals, and CDMO/CRO services. Revenue is generated through direct sales, e-commerce, and enterprise contracts with pharmaceutical and biotechnology companies.
2. CDMO and CRO Services (PPD & Patheon): Thermo Fisher generates significant revenue through its Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) services via the PPD and Patheon brands. Services include Phase 3 manufacturing, clinical research, commercial manufacturing, API, biologics, viral vector services, GMP plasmids, and clinical trial solutions. Revenue is project-based and recurring from long-term partnerships.
3. Clinical Diagnostics: Revenue from clinical diagnostic products and services including transplant diagnostics (HLA typing, antibody detection), blood screening and genotyping, oncology companion diagnostics, and pharmacogenomic testing. Distributed through clinical laboratories and healthcare providers.
4. Instrument Services and Support (Unity Lab Services): Recurring revenue from instrument service plans, calibration, compliance services, maintenance, and enterprise asset management. Service Central platform provides 24/7 service request management, preventive maintenance scheduling, and real-time ticket tracking.
5. Research and Life Sciences Consumables: Revenue from antibodies, cell culture media, chemicals, chromatography columns, lab plasticware, microplates, oligos, primers, probes, genes, and TaqMan assays sold through the Fisher Scientific e-commerce marketplace and direct sales.

Pricing tiers

Go-to-market motion3 records

Distribution channels7 records

Marketing channels8 records

Core offering

Thermo Fisher Scientific manufactures and distributes scientific instruments (mass spectrometers, electron microscopes, PCR systems, sequencers, microarrays), specialty consumables and reagents (antibodies, cell culture media, chromatography columns, oligos), and clinical diagnostic products. The company also delivers end-to-end biopharma services through its PPD clinical research organization and Patheon CDMO, supported by a global Fisher Scientific distribution marketplace offering over 2.5 million products.

Product overview

Thermo Fisher Scientific operates as a diversified life sciences conglomerate organized around multiple sub-brands and product lines that serve research, biopharma, clinical diagnostics, and industrial markets. The core product portfolio spans mass spectrometry (Orbitrap Tribrid Apex, Orbitrap Excedion, Orbitrap Exploris GC S), molecular diagnostics (Applied Biosystems brand including RapidHIT ID System, TaqMan Real-Time PCR Assays, and the new SwiftArrayStudio Microarray Analyzer), and advanced genomics/proteomics platforms. The Olink Proteomics platform (acquired brand) provides high-throughput protein biomarker analysis via proximity extension assay technology, including the Olink Explore, Olink Reveal, and Olink Target product lines. The company also operates extensive CDMO/CRO services through Patheon (API, biologics, viral vectors, commercial manufacturing across 60+ global sites) and PPD Clinical Research (clinical development, bioanalytical and biomarker laboratory services, CorEvitas real-world evidence registries). One Lambda (transplant diagnostics brand) provides HLA typing, antibody detection, and blood screening solutions including the LABScreen Multi assay and LinkSeq genotyping kits. Following the acquisition of Solventum's Purification & Filtration business, Thermo Fisher added bioprocessing filtration, industrial filtration, and membrane products to its portfolio. Strategic acquisitions including Clario Holdings (digital endpoint data solutions for clinical trials), HealthVerity, Datavant, MSAID, and Proteinaceous strengthen AI-enabled workflows and data intelligence. The Fisher Scientific marketplace channel distributes over 2.5 million products globally, while Unity Lab Services and the Service Central digital platform provide after-market instrument servicing, compliance, and asset management. The Accelerator Drug Development model integrates CDMO and CRO capabilities to reduce operational fragmentation for biopharma customers.

Differentiator

Problem solved

Functional benefit

Brands

• Olink Explore: High-throughput proteomics platform for analyzing 5,400+ proteins simultaneously with exceptional specificity and scalability.
• Olink Reveal
• Olink Target
• Olink Flex
• Olink Focus
• Olink Signature
• LinkSēq
• LABScreen Multi
• Accelerator Drug Development
• CorEvitas

Products and services

• Accelerator Drug Development Integrated CDMO-CRO platform combining manufacturing and clinical research capabilities to reduce operational fragmentation for biotech and pharma customers, with end-to-end development and commercial manufacturing services.
• Olink Proteomics Platform Affinity-based proteomics platform using Proximity Extension Assay (PEA) technology for highly sensitive and accurate high-throughput protein biomarker analysis, enabling biomarker discovery, validation, and population-scale proteogenomics.
• Orbitrap Tribrid Apex Mass Spectrometer Next-generation Orbitrap mass spectrometry platform delivering up to five times greater sensitivity and up to 100% sequence coverage in a single experiment for proteomics, structural biology, and biopharma characterization applications.
• Orbitrap Excedion Mass Spectrometer Mass spectrometry platform for drug development with enhanced dynamic range, detecting 3-5x more compounds in complex samples to support regulatory-ready data packages.
• Orbitrap Exploris GC S Mass Spectrometer Gas chromatography-Orbitrap mass spectrometry platform targeting environmental and food safety testing applications.
• Applied Biosystems RapidHIT ID System with RapidINTEL Plus Cartridge Rapid DNA workflow system that received the first FBI NDIS approval for generating qualifying crime scene DNA profiles eligible for CODIS database searches, producing investigative DNA leads in approximately 90 minutes.
• Applied Biosystems SwiftArrayStudio Microarray Analyzer Next-generation microarray device combining multiple genotyping processes into one platform, enabling faster Genome-Wide Association Studies and pharmacogenomics analyses.
• Glacios 3 Cryo-TEM Advanced cryo-transmission electron microscope extending 3D imaging capabilities for neuroscience, oncology, and cardiology research applications.
• Patheon CDMO Services End-to-end pharma services providing CDMO offerings including API, biologics, viral vector services, cGMP plasmids, early- and late-phase development, clinical trial solutions, logistics, and commercial manufacturing across more than 60 global locations.
• PPD Clinical Research Services Clinical development and analytical services enabling customers to accelerate innovation across early development, all phases of clinical trials, peri- and post-approval, and comprehensive laboratory services including bioanalytical and biomarker testing.
• TaqMan Real-Time PCR Assays Industry-leading real-time PCR assays for gene expression, SNP genotyping, and copy number variation analysis used across basic, clinical, and commercial research applications.
• Invitrogen Primary Antibodies Advanced validation and coverage antibody products maximizing lab budgets with high-performance primary antibodies for research applications including Western blotting, flow cytometry, and immunoassays.
• Gibco Cell Culture Media and Bioproduction Products Cell culture media and bioproduction products including serum-free media formulations supporting biopharmaceutical production and cell therapy research.
• One Lambda Transplant Diagnostics Testing solutions for HLA labs and transplant clinical teams providing personalized patient care across the transplant journey, including HLA typing, antibody detection and monitoring, and transplant lab analysis software.
• LABScreen Multi Blood Screening Assay FDA-cleared assay for simultaneous detection of HLA and HNA antibodies in a single well, designed to mitigate TRALI risk in plasma transfusions, capable of screening up to 96 samples in less than 4 hours.
• LinkSeq Real-Time PCR Molecular Antigen Typing Kits Real-time PCR molecular antigen typing kits for rapid blood genotyping, predicting ABO phenotypes including subgroups and HPA antigens with 90-minute DNA-to-results turnaround and minimal hands-on time.
• Unity Lab Services Specialized end-to-end laboratory service and support including instrument servicing, asset management, supply management, scientific support, and regulatory compliance services delivered by over 2,000 factory-certified engineers globally.
• Olink Explore High-throughput proteomics product line analyzing 5,400+ proteins simultaneously with exceptional specificity and scalability for advanced disease research and biomarker discovery.
• Olink Reveal Accessible NGS-based proteomics solution analyzing 1,000 proteins with curated content for translational and immune-related research, using pre-dried reagents in 96-well plates with under 2.5 hours hands-on time.
• Olink Target Targeted panels of 96 or 48 proteins with high specificity and sensitivity, with options for relative or absolute quantification, supporting biomarker validation and clinical research.
• GeneArt Gene Synthesis Services Custom gene synthesis services enabling DNA construction for research and drug discovery applications.
• Chromatography Columns and Cartridges Chromatography columns and cartridges for analytical and preparative separation applications in pharmaceutical, biotechnology, and industrial research.
• Solventum Purification and Filtration Bioprocessing Products Bioprocessing purification, industrial filtration, and membrane solutions for OEMs acquired from Solventum Corporation, enhancing bioproduction offerings with advanced filtration technologies.
• Clario Digital Endpoint Data Solutions Digital endpoint data solutions and electronic Clinical Outcome Assessments for clinical trials, supporting a significant portion of FDA drug approvals.
• Service Central Online platform enabling customers to manage instruments and equipment, submit and track service requests 24/7, schedule preventive maintenance, access service history, and request on-demand service quotes.
• Lab Informatics Solutions Digital solutions for laboratory information management, electronic lab notebooks, and data integration across scientific workflows.
• VeriFlex Pre-Transplant Risk Assessment Assay Pre-transplant risk assessment assay using transcriptomics, with clinical validation showing high-risk kidney transplant patients are seven times more likely to experience early acute rejection.

Quantifiable outcome

• Detects approximately 1,000 proteins via Olink Reveal NGS-based proteomics with R=0.96-0.98 reproducibility between research groups
• +4 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability14 records

Feature13 records

Partnerships

Ten partnerships are on record, tiered major, core and minor.

• SanofimajorStrategic or Co-development Partner · 7 July 2026Thermo Fisher acquired a sterile fill-finish site from Sanofi to expand its biopharmaceutical manufacturing capabilities, as highlighted in market research on biopharmaceutical processing equipment. The acquisition enhances Thermo Fisher's capacity for biologics drug substance and fill-finish manufacturing.
• Arcturus TherapeuticscoreStrategic or Co-development Partner · 2 July 2026Strategic manufacturing collaboration for Phase 3 development and potential commercialization of ARCT-032, Arcturus' investigational mRNA therapy for cystic fibrosis. Under a five-year Master Services Agreement, Thermo Fisher provides up to $40M in clinical manufacturing services and $40M in CRO services via its PPD business, with exclusive commercial manufacturing rights upon regulatory approval. The collaboration leverages Thermo Fisher's Accelerator Drug Development solutions and PPD clinical research capabilities.
• Benchmark GeneticsminorStrategic or Co-development Partner · 1 July 2026Collaboration with six European research institutions and Thermo Fisher Scientific to develop a high-density SNP array for Manila clam and grooved carpet shell clam genomic mapping. The array contains 49,392 genetic markers for Manila clam and 14,193 for grooved carpet shell clam, developed by screening more than 300 million genetic variants using Thermo Fisher technology, supporting selective breeding for European aquaculture.
• NVIDIAcoreTechnology or Integration · 22 June 2026Strategic AI partnership announced at BIO International 2026 to advance AI-enabled workflows and data intelligence offerings for pharmaceutical and biotechnology customers. Part of a suite of AI partnerships including OpenAI, TetraScience, and BenchSci to strengthen Thermo Fisher's AI capabilities.
• TetraSciencecoreTechnology or Integration · 22 June 2026Strategic AI and data intelligence partnership announced at BIO International 2026 to strengthen AI-enabled workflows. TetraScience provides data integration and lab informatics capabilities complementing Thermo Fisher's instrument and software portfolio.
• BenchScicoreTechnology or Integration · 22 June 2026Strategic AI partnership announced at BIO International 2026. BenchSci provides AI-enabled literature and experiment analysis capabilities that complement Thermo Fisher's instrument and reagent portfolio for drug discovery applications.
• SHL MedicalmajorStrategic or Co-development Partner · 22 June 2026Collaboration to expand global sterile fill-finish capacity at the Ridgefield, New Jersey site. SHL Medical provides advanced fill-finish solutions and autoinjector capabilities, complementing Thermo Fisher's CDMO manufacturing infrastructure for biopharmaceutical customers.
• OpenAIcoreTechnology or Integration · 16 June 2026Partnership with OpenAI to integrate GPT-Rosalind, a specialized AI reasoning model for life sciences research covering drug discovery, biology, and translational medicine, available in ChatGPT, Codex, and API for qualified enterprise customers. Thermo Fisher Scientific is listed among pharmaceutical and biotechnology firms (alongside Amgen and Moderna) partnering with OpenAI to apply the model across scientific workflows.
• Clario Holdings Inc.coreStrategic or Co-development Partner · 29 October 2025Thermo Fisher agreed to acquire Clario Holdings Inc. in an $8.875 billion cash transaction to enhance capabilities in digital endpoint data solutions for clinical trials. Clario supports a significant portion of FDA drug approvals with its electronic Clinical Outcome Assessments and AI solutions. The acquisition was completed in March 2026.
• Solventum CorporationcoreStrategic or Co-development Partner · 1 February 2025Thermo Fisher acquired Solventum Corporation's Purification & Filtration business for approximately $4.1 billion in February 2025. The acquisition strengthens the bioprocessing portfolio with advanced filtration technologies for upstream and downstream workflows, industrial filtration, and membrane solutions for medical and semiconductor applications.

Scale indicators13 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Danaher Corporation: Danaher is a diversified life sciences and diagnostics conglomerate operating Beckman Coulter, Cytiva, Leica Biosystems, and Pall. It competes directly with Thermo Fisher in bioprocessing (Cytiva vs Patheon), diagnostics (Beckman Coulter), and lab instruments, with similar end-market exposure and a comparable $200B+ scale profile.
• Roche Diagnostics: Roche is a broad incumbent competitor in clinical diagnostics, transplant diagnostics (HLA typing), molecular diagnostics, and companion diagnostics, overlapping with Thermo Fisher's One Lambda transplant diagnostics and clinical diagnostics business across hospital and reference lab channels.

Direct peers

• Agilent Technologies: Agilent is a direct competitor in analytical instruments (mass spectrometry, chromatography) and life sciences consumables, serving the same pharmaceutical, biotech, academic, and applied markets. Cross-competition in GC-MS, LC-MS, and chromatography consumables makes Agilent the closest like-for-like instrument peer.
• Waters Corporation: Waters is a direct competitor in high-performance liquid chromatography (HPLC) and mass spectrometry, with the ACQUITY and Xevo product lines overlapping Thermo Fisher's Vanquish and Orbitrap platforms in pharma QC and research workflows.
• Bruker Corporation: Bruker competes directly in mass spectrometry (timsTOF, MALDI-TOF), nuclear magnetic resonance (NMR), and cryo-electron microscopy infrastructure — overlapping with Thermo Fisher's Orbitrap, EM, and structural biology platforms in pharma and academic research.
• Bio-Rad Laboratories: Bio-Rad is a direct competitor in life science research tools, clinical diagnostics, and digital PCR (ddPCR), with overlapping products in western blotting, qPCR, and clinical chemistry that compete with Applied Biosystems and Invitrogen product lines.
• Lonza Group: Lonza is a direct competitor in biologics CDMO services, including cell and gene therapy manufacturing, mammalian and microbial production — overlapping with Patheon's biopharma services and competing for the same biotech and pharma outsourcing customers.
• Catalent (Novo Holdings): Catalent is a direct competitor in pharmaceutical CDMO services, particularly in softgel, oral dose forms, biologics fill-finish, and cell therapy. Acquired by Novo Holdings in 2024, it remains a core competing CDMO for pharma outsourcing customers alongside Patheon.
• IQVIA: IQVIA is a direct competitor to PPD (Thermo Fisher's CRO business) in clinical research services, biopharma data analytics, and real-world evidence — overlapping with CorEvitas and Clario's clinical trial endpoint offerings across pharma and biotech customers.

Regional players

• Shimadzu Corporation: Shimadzu is a Japanese-headquartered analytical instrument manufacturer competing in mass spectrometry (LC-MS, GC-MS), chromatography, and spectroscopy — overlapping product categories with Thermo Fisher's instruments, but with stronger Asia-Pacific presence and different geographic footprint in North America and Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/thermo-fisher-scientific
• Xx.com/ThermoFisher
• Facebookfacebook.com/thermoscientific

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries15 records

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A71 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thermo Fisher Scientific